Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration

被引:9
作者
Rodríguez, JC [1 ]
Cebrián, L [1 ]
López, M [1 ]
Ruiz, M [1 ]
Royo, G [1 ]
机构
[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Secc Microbiol, Alicante 03203, Spain
关键词
mutant prevention concentration; fluoroquinolones; linezolid; macrolides; Mycobacterium avium-intracellulare;
D O I
10.1016/j.ijantimicag.2004.09.018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study looked the selection of resistant mutants in Mycobacterium avium-intracellulare during antibiotic treatment. The mutant prevention concentration (MPC) of 20 Mycobacterium avium and 12 Mycobacterium intracellulare isolates was determined. Fifty percent of Mycobacterium avium strains had MPC (MPC50) values lower than 16, 64, 40, 55 and 60 mg/L for rifabutin, rifampicin, ciprofloxacin, levofloxacin and moxifloxacin, respectively. In the case of Mycobacterium intracellulare, 50% had MPC (MPC50) values below 60, 30, 35, 16, 2.5 and 14 mg/L for linezolid, rifabutin, levofloxacin, gatifloxacin, moxifloxacin and clarithromycin, respectively. The high capacity for selecting resistant mutants of all the antibiotics studied emphasises the need to restore the immune system if necessary and to administer combined treatments in order to cure patients. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 36 条
[1]   A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex:: AIDS Clinical Trial Group 393 Study Team [J].
Aberg, JA ;
Williams, PL ;
Liu, T ;
Lederman, HM ;
Hafner, R ;
Torriani, FJ ;
Lennox, JL ;
Dube, MP ;
MacGregor, RR ;
Currier, JS .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (07) :1046-1052
[2]  
Apseloff G, 1998, J CLIN PHARMACOL, V38, P830
[3]   Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS:: A randomized, double-blind, placebo-controlled trial [J].
Benson, CA ;
Williams, PL ;
Cohn, DL ;
Becker, S ;
Hojczyk, P ;
Nevin, T ;
Korvick, JA ;
Heifets, L ;
Child, CC ;
Lederman, MM ;
Reichman, RC ;
Powderly, WG ;
Notario, GF ;
Wynne, BA ;
Hafner, R .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1289-1297
[4]   Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease [J].
Bermudez, LE ;
Kolonoski, P ;
Petrofsky, M ;
Wu, M ;
Inderlied, CB ;
Young, LS .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1977-1980
[5]   Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium [J].
Bermudez, LE ;
Inderlied, CB ;
Kolonoski, P ;
Petrofsky, M ;
Aralar, P ;
Wu, M ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :217-222
[6]   Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy [J].
Bermudez, LE ;
Petrofsky, M ;
Kolonoski, P ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :180-183
[7]   Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice [J].
Bermudez, LE ;
Nash, K ;
Petrofsky, M ;
Young, LS ;
Inderlied, CB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2619-2622
[8]   Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome [J].
Cohn, SE ;
Kammann, E ;
Williams, P ;
Currier, JS ;
Chesney, MA .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1129-1136
[9]   Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg [J].
Danesi, R ;
Lupetti, A ;
Barbara, C ;
Ghelardi, E ;
Chella, A ;
Malizia, T ;
Senesi, S ;
Angeletti, CA ;
Del Tacca, M ;
Campa, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :939-945
[10]   In vitro activity of new fluoroquinolones and linezolid against nontuberculous mycobacteria [J].
Díaz, JCR ;
López, M ;
Ruiz, M ;
Royo, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 21 (06) :585-588